Efficacy, durability, and safety of intravitreal faricimab with
extended dosing up to every 16 weeks in patients with
diabetic macular edema (YOSEMITE and RHINE):
two randomized, double-masked, phase 3 trials
Aflibercept 8 mg for Diabetic Macular Edema: 2-Year Results of the Phase 2/3 PHOTON Trial
Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial
Intravitreal aflibercept 8 mg injection for DME: 48-week results from the Phase 2/3 PHOTON trial
Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomized, double-masked, phase 3 trials
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
Visual Acuity Outcomes and Anti-VEGF Therapy Intensity in Diabetic Macular Oedema: A Real-World Analysis of 28,658 Patient Eyes
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial
Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor (VEGF) vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy (DR): The Protocol W Randomized Clinical Trial
Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial
The Short-term Effect of a Single Lapse in Anti–Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema (DME) Within Routine Clinical Practice
Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial
Diabetic retinopathy severity and peripheral lesions are associated with nonperfusion on ultrawide field angiography
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema (DME)
Baseline factors affecting changes in diabetic retinopathy (DR) severity scale score after intravitreal aflibercept or laser for diabetic macular edema (DME)
Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema (DME) following anti-vascular endothelial growth factor treatment across trials
Ranibizumab 0.5mg Treat-and-Extend Regimen for Diabetic Macular Edema (DME): The RETAIN Study
Twenty-Four-Month Optical Coherence Tomography Assessment (OCTA) in Diabetic Patients Undergoing Fixed-Interval Intravitreal Aflibercept Therapy
Preoperative Bevacizumab for Tractional Retinal Detachment in Proliferative Diabetic Retinopathy: A Prospective Randomized Clinical Trial
Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial
Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema